test

Steve Giordano

@Casdin Capital, Llc

Latest period2024 - Q3ReportedManaged Assets$1.5BTotal holdings35
Assets growth rate14.98%Assets growth rate (2-Q avg)5.98%Continuous growth in asset value1 quarters

Portfolio positions

This chart displays the top 10 holdings in Casdin Capital, Llc's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 35 positions.

Assets under management

The assets under management (AUM) of Casdin Capital, Llc over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 1.5B in assets, with a quarterly growth rate of 14.98% and a 2-quarter average growth rate of 5.98%. The portfolio is managed by Steve Giordano, and others.

Portfolio holdings

CurrentNew PositionIncreasedDecreasedExited
InvestmentPortfolio %Reported Value
BLFSBiolife Solutions Inc
Recent Activity
14.54%
$218.027M
8.707M shares@ $25.05 avg price
RVMDRevolution Medicines Inc
Recent Activity
Decreased -6.63%
12.44%
$186.583M
4.114M shares@ $45.35 avg price
WGSGenedx Holdings Corp
Recent Activity
Decreased -0.54%
9.93%
$148.844M
3.507M shares@ $42.44 avg price
LABStandard Biotools Inc
Recent Activity
Increased 11.41%
9.17%
$137.522M
71.255M shares@ $1.94 avg price
SRPTSarepta Therapeutics Inc
Recent Activity
8.94%
$134.069M
1.073M shares@ $124.89 avg price
ILMNIllumina Inc
Recent Activity
Increased 56.25%
6.53%
$97.808M
750,000 shares@ $130.41 avg price
RNAAvidity Biosciences Inc
Recent Activity
6.39%
$95.757M
2.085M shares@ $45.93 avg price
RLAYRelay Therapeutics Inc
Recent Activity
Increased 9.5%
4.37%
$65.498M
9.251M shares@ $7.09 avg price
ALNYAlnylam Pharmaceuticals Inc
Recent Activity
3.12%
$46.755M
170,000 shares@ $275.03 avg price
EXASExact Sciences Corp
Recent Activity
2.96%
$44.278M
650,000 shares@ $68.12 avg price